Fate Therapeutics Inc
FATE Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$2.06
KIRA · Stoqly’s AI analyst, in plain words
- Fate Therapeutics Inc had $6.6M of revenue in fiscal 2025, down 51.2% on the year before. Over five years, revenue changed −26.7% a year on average.
- Its operating margin was −2,222.4%, down 679.8 pts: of every 100 in sales, about −2,222 is left after running the business.
- Fate Therapeutics Inc lost $136M in fiscal 2025.
- Free cash flow was −$112M in fiscal 2025, −1,685.8% of revenue.
Market cap
$247M
P/E
—
Revenue
$6.6M
Net income
−$136M
Free cash flow
−$112M
Operating margin
−2,222.4%
Fate Therapeutics Inc in 30 seconds · fiscal 2025
Are sales growing?
−51.2%
No. Sales fell 51.2% last year.
Does it make a profit?
−2,051.1%
No. It lost money last year.
Does profit turn into cash?
−1,685.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Fate Therapeutics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- FATE THERAPEUTICS INC
- CIK
- 0001434316
Fate Therapeutics Inc · FATE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Revenue growth | 77.7% | 72.4% | −34.0% | −78.5% | −51.2% |
| Operating margin | −388.6% | −320.2% | −299.9% | −1,542.6% | −2,222.4% |
| Net income | −$212M | −$282M | −$161M | −$186M | −$136M |
| Net margin | −379.9% | −292.5% | −253.3% | −1,366.5% | −2,051.1% |
| Diluted EPS | −$2.24 | −$2.91 | −$1.64 | −$1.64 | −$1.15 |
| Cash | |||||
| Cash from operations | −$163M | −$248M | −$132M | −$123M | −$106M |
| Capital expenditure | $50.7M | $35.6M | $6.2M | $0.7M | $6.0M |
| Free cash flow | −$214M | −$284M | −$138M | −$124M | −$112M |
| FCF margin | −382.4% | −294.7% | −217.9% | −906.8% | −1,685.8% |
| Share count change | 15.0% | 2.2% | 1.6% | 15.5% | 4.5% |
| Debt and strength | |||||
| Cash and short-term investments | $616M | $436M | $315M | $279M | $204M |
| Shareholders' equity | $679M | $484M | $368M | $319M | $207M |
| Current ratio | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Returns and quality | |||||
| Return on equity | −39.9% | −48.5% | −37.8% | −54.2% | −51.8% |
| Return on tangible equity | −31.3% | −58.2% | −43.7% | −58.4% | −65.8% |
| Piotroski F-score | 4 | 2 | 3 | 1 | 1 |
| Altman Z'' | 2.6 | −1.9 | −3.7 | −7.0 | −13.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.3M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fate Therapeutics Inc · FATE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.06 a share, the company is worth $247M.
Source: SEC EDGAR XBRL filings (CIK 0001434316). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.